Search Results |
|
|
Total: 33837 |
Page
of 3384 
|
Continuous-Flow Generation of Hyperpolarized Liquids for Improving Magnetic Resonance Imaging (MRI) Sensitivity
Hyperpolarization of Metabolites Enhances MRI Image Quality and Diagnostic UtilityMagnetic resonance imaging (MRI) is … moreHyperpolarization of Metabolites Enhances MRI Image Quality and Diagnostic UtilityMagnetic resonance imaging (MRI) is a foundational tool in clinical diagnostics with the ability to produce detailed, non-invasive images of internal anatomy and function. Over 100 million scans are performed annually, and the market is projected to reach $10.3 billion by 2030 . However, current MRI techniques face significant limitations in chemically selective metabolic imaging. Sensitivity is often too low to detect key metabolites at physiological concentrations, and strong background signals from water and fat obscure molecular details. Competing modalities such as CT and PET can provide metabolic information, but they rely on ionizing radiation, offer limited chemical specificity, and lack anatomical detail.
Researchers at the University of Florida have developed a continuous-flow system for generating hyperpolarized metabolites using parahydrogen-induced polarization (PHIP). It leverages parahydrogen as a source of nuclear spin order, amplifying MRI signal strength and enabling real-time, chemically selective imaging of metabolic processes. Unlike traditional batch-based hyperpolarization methods, the continuous-flow approach sustains production and delivery of hyperpolarized agents, supporting extended imaging sessions and improved diagnostic accuracy. By overcoming key barriers in sensitivity, workflow efficiency, and patient safety, this technology offers transformative potential for clinical and research applications.
ApplicationA device for continuous-flow parahydrogen-induced hyperpolarization of metabolites in aqueous solution for advanced metabolic MRI
Advantages
TechnologyThis technology integrates a continuous-flow hydrogenation reactor with parahydrogen-induced polarization, allowing for the rapid and sustained generation of hyperpolarized metabolites in aqueous solution. By combining a spin order transfer device and advanced membrane-based separation, the system efficiently produces purified imaging agents, overcoming the limitations of batch-based methods and enabling real-time, high-sensitivity metabolic imaging with MRI. The modular design supports seamless integration into clinical workflows and ensures rapid extraction and purification, delivering hyperpolarized agents in seconds and facilitating extended imaging sessions for improved diagnostic precision. less |
Primary:
University of Florida
Date posted: Jan 16, 2026 |
|
|
Development of SelU Inhibitors as New Antibiotics
Scientists discovered that special chemical modifications on bacterial tRNA help control protein production and stress… moreScientists discovered that special chemical modifications on bacterial tRNA help control protein production and stress responses. They have also developed novel compounds that take advantage of this mechanism to produce antibiotic effects. Background: The field of epitranscriptomics focuses on the chemical modifications of RNA molecules, which are increasingly recognized as crucial regulators of gene expression and cellular function. Among the various RNA species, transfer RNAs (tRNAs) are the most extensively modified, with these modifications playing essential roles in maintaining tRNA stability, ensuring accurate translation, and modulating the speed and fidelity of protein synthesis. Recent research has highlighted the dynamic nature of these modifications, particularly under stress conditions, where cells can reprogram their tRNA modification patterns to adapt to environmental changes. This growing understanding has underscored the importance of tRNA modifications in bacterial physiology and their potential as targets for novel therapeutic interventions. Despite the recognized significance of tRNA modifications, current approaches to studying and targeting these systems face several challenges. Traditional antibiotics often target ribosomal subunits or essential enzymes, but bacteria can rapidly develop resistance through mutations or efflux mechanisms. Furthermore, many of the enzymes responsible for tRNA modifications have complex substrate specificities and catalytic mechanisms that are not fully understood, making them difficult to inhibit selectively. Existing methods for probing the function of these modifications are also limited by the lack of specific inhibitors and the difficulty in distinguishing the effects of individual modifications from broader cellular processes. As a result, there is a pressing need for new strategies that can selectively disrupt bacterial tRNA modification pathways without affecting similar processes in host cells, thereby providing a novel avenue for antibiotic development and overcoming the limitations of current antimicrobial therapies. Technology Overview: The small molecule technology centers on the dynamic modification of transfer RNA (tRNA) molecules through a series of chemical changes that regulate protein translation in bacteria. What differentiates this technology is its exploitation of the unique bacterial tRNA modification pathway as a novel antibiotic target. Research has shown that bacteria lacking the targeted enzyme are more susceptible to ribosome-targeting antibiotics like chloramphenicol, suggesting that this enzyme is essential for robust protein synthesis under antibiotic stress. By designing small molecules that specifically bind to the active site of these enzymes using the enzyme’s natural substrate as a template—researchers have developed lead compounds that inhibit the target enzyme function with high affinity. This approach is highly selective, as the targeted pathway is unique to bacteria, minimizing the risk of off-target effects in human cells and offering a promising route for the development of next-generation antibiotics that circumvent traditional resistance mechanisms. https://suny.technologypublisher.com/files/sites/adobestock_554085762.jpeg Advantages: • Unique bacterial-specific modifications offer selective targeting opportunities. • A promising antibiotic target for gram negative bacteria, enabling development of novel antimicrobial agents. • Small molecule inhibitors show potential for disrupting bacterial translation and combating antibiotic resistance. Applications: • Novel antibiotic drug development • Bacterial stress response modulation • Selective bacterial translation inhibition Intellectual Property Summary: Patent application filed Stage of Development: • TRL 3 • https://en.wikipedia.org/wiki/Technology_readiness_level Licensing Status: This technology is available for licensing. less |
Primary:
Research Foundation of SUNY
Date posted: Jan 16, 2026 |
|
|
DarWin American chestnut trees with inducible expression of an oxalate oxidase transgene
The DarWin American chestnut tree is genetically engineered to activate a wheat gene only when attacked… moreThe DarWin American chestnut tree is genetically engineered to activate a wheat gene only when attacked by blight, helping it resist disease more efficiently and grow better, supporting forest restoration and improved plant health. Background: The American chestnut tree was once a dominant species in eastern North American forests, valued for its ecological role and high-quality timber. However, the accidental introduction of the chestnut blight fungus (Cryphonectria parasitica) in the early 20th century led to the near-extinction of mature American chestnuts, fundamentally altering forest ecosystems and causing significant economic and environmental losses. Restoration of the American chestnut has become a major focus for conservationists, plant breeders, and forestry organizations. The primary challenge is developing trees that can resist or tolerate the blight, thereby enabling the reestablishment of this iconic species in its native range. Current approaches to conferring blight resistance in American chestnut trees have included traditional breeding with Asian chestnut species, which are naturally resistant, and genetic engineering strategies such as the introduction of genes encoding oxalate oxidase enzymes. However, many of these transgenic lines utilize constitutive promoters that drive continuous, unregulated expression of the resistance gene in all tissues at all times. This constant expression can impose a significant metabolic burden on the plant, potentially slowing growth rates and reducing overall vigor, especially under normal, non-infectious conditions. As a result, while these trees may exhibit improved blight tolerance, their fitness and competitiveness in natural forest environments may be compromised, limiting the effectiveness of restoration efforts. Technology Overview: The DarWin American chestnut is a genetically engineered tree designed to combat chestnut blight by expressing a wheat-derived oxalate oxidase gene. This gene encodes an enzyme that breaks down oxalic acid, a compound produced by the blight fungus to facilitate infection. A key feature of this technology is the use of an inducible promoter, which activates oxalate oxidase expression only when the tree is wounded or under pathogen attack, rather than maintaining constant expression. This targeted response is intended to conserve the tree’s metabolic resources, potentially supporting faster growth and greater overall health. The DarWin line includes not only the original transgenic plant but also its direct offspring and homozygous derivatives, expanding its utility for breeding and restoration efforts. What differentiates this technology is its inducible gene expression system, which marks a significant improvement over previous approaches that relied on constitutive (constant) gene activation. By limiting the production of oxalate oxidase to periods of actual threat, the DarWin chestnut minimizes unnecessary metabolic expenditure, which can otherwise hinder growth and vigor. This innovation enables the tree to allocate more resources to normal development under non-stress conditions, while still mounting a robust defense when challenged by blight. The inducible system also opens possibilities for broader application in other crops or trees facing similar pathogenic challenges, making it a versatile and efficient solution for disease resistance in plant biotechnology. https://suny.technologypublisher.com/files/sites/adobestock_57166791.jpeg Advantages: • Enhanced tolerance to chestnut blight through targeted degradation of oxalic acid, a key fungal virulence factor. • Inducible gene expression system activates oxalate oxidase only upon wounding or pathogen infection, improving metabolic efficiency. • Potential for faster growth rates compared to trees with constitutive gene expression due to reduced metabolic burden. • Supports restoration of American chestnut populations affected by blight. • Enables breeding programs to develop further blight-resistant American chestnut lines. • Applicability of the inducible expression system to other crops or tree species facing similar pathogen challenges. • Includes direct offspring and homozygous derivatives, facilitating advanced breeding and propagation. Applications: • Forest restoration with blight-resistant trees • Commercial timber production • Breeding blight-resistant chestnut varieties • Conservation reforestation projects Intellectual Property Summary: Patent application filed Stage of Development: • TRL 7. Trees have been grown and tested against blight. • https://en.wikipedia.org/wiki/Technology_readiness_level Licensing Status: This technology is available for nonexclusive licensing less |
Primary:
Research Foundation of SUNY
Date posted: Jan 16, 2026 |
|
|
Rapid, robust, and near point-of-care saliva-based nucleic acid detection of dengue virus infections
This technology enables rapid, non-invasive detection and differentiation of all four dengue virus serotypes using… moreThis technology enables rapid, non-invasive detection and differentiation of all four dengue virus serotypes using saliva samples, with advanced qPCR and RT-LAMP assays, making dengue diagnosis easier, faster, and more accessible without the need for blood draws. Background: Dengue virus (DENV) is a major global health concern, with hundreds of millions of infections occurring annually, particularly in tropical and subtropical regions. Accurate and timely diagnosis is crucial for effective patient management and for controlling outbreaks, especially since infection with one DENV serotype can increase the risk of severe disease upon subsequent infection with a different serotype. Traditionally, DENV diagnostics have relied on blood-based methods, which require trained phlebotomists, specialized equipment, and can be invasive and uncomfortable for patients. This reliance on blood samples poses significant challenges in resource-limited settings, where access to healthcare infrastructure and skilled personnel may be limited, and where rapid, large-scale testing is often needed during outbreaks. Current diagnostic approaches for DENV, such as conventional PCR and serological tests, face several limitations. Blood-based PCR assays, while sensitive, often require complex sample preparation, including RNA purification, and are susceptible to inhibitors present in crude samples, which can compromise accuracy. Serological assays, on the other hand, may not reliably distinguish between DENV serotypes or between primary and secondary infections, leading to potential misdiagnosis. Furthermore, the need for cold chain storage, specialized reagents, and laboratory infrastructure restricts the deployment of these tests in field or point-of-care settings. These challenges highlight the need for more accessible, rapid, and non-invasive diagnostic solutions that can be implemented widely, particularly in outbreak-prone and resource-constrained environments. Technology Overview: This technology provides a rapid, non-invasive diagnostic solution for detecting and differentiating all four dengue virus (DENV) serotypes using saliva samples. It integrates two advanced nucleic acid testing methods: a multiplex quantitative PCR (qPCR) assay and a reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay. The multiplex qPCR can simultaneously identify DENV1–4 and a human internal control in under 90 minutes, with high sensitivity down to 3–5 viral RNA copies per microliter, and is compatible with both purified and crude saliva samples. The RT-LAMP assay, operating at a single temperature, delivers serotype-specific results in as little as 7–15 minutes and supports simple colorimetric or lateral-flow readouts, making it suitable for point-of-care settings. Both methods use standard commercial reagents and are designed for ease of use, eliminating the need for trained phlebotomists and enabling deployment in resource-limited environments. This technology is differentiated by its comprehensive approach to dengue diagnostics, leveraging large-scale genomic analysis to design highly specific primers and probes that ensure accurate serotype identification directly from saliva. Unlike traditional blood-based tests, this solution offers a non-invasive alternative that is easier to administer and more acceptable to patients, particularly in mass screening or pediatric contexts. The assays have been validated through rigorous human challenge studies and transcriptomic analyses, demonstrating comparable sensitivity and specificity to blood-based methods while also providing insights into host immune responses. Its compatibility with digital PCR and whole-genome sequencing further enhances its utility for research and epidemiological surveillance. The combination of rapid turnaround, high accuracy, non-invasive sampling, and adaptability to point-of-care use positions this technology as a significant advancement in global dengue management and public health diagnostics. https://suny.technologypublisher.com/files/sites/adobestock_349162542.jpeg Advantages: • Non-invasive detection of all four Dengue virus serotypes using saliva samples, eliminating the need for blood draws. • Rapid results with multiplex qPCR providing detection in under 90 minutes and RT-LAMP assays delivering results within 7–15 minutes. • High sensitivity and specificity by targeting conserved, serotype-distinct genomic regions, with detection limits as low as ~3 copies/µL. • Compatibility with point-of-care settings due to tolerance of crude saliva inhibitors and use of standard commercial enzymes and reagents. • Supports multiple readout formats including fluorescent, colorimetric, and lateral-flow assays for flexible diagnostic use. • Enables viral RNA quantification and whole-genome sequencing directly from saliva, facilitating detailed viral analysis and surveillance. • Reduces reliance on trained medical personnel and specialized equipment, improving accessibility in resource-limited environments. • Potential to enhance understanding of host immune responses through saliva transcriptomic analysis alongside viral detection. Applications: • Point-of-care dengue screening • Rapid outbreak surveillance • At-home dengue self-testing • Clinical trial participant monitoring • Travel health screening Intellectual Property Summary: Patent application filed: 63/924,381, filed on 11/24/2025 Know-how based Stage of Development: Design of highly specific primers and probes in hand, that ensure accurate serotype identification directly from saliva. TRL level 4. Licensing Status: This technology is available for licensing. less |
Primary:
Research Foundation of SUNY
Date posted: Jan 16, 2026 |
|
|
Lipid nanoparticles for targeted delivery of therapeutic agents in acute lung injury
This technology uses lung-targeting lipid nanoparticles to deliver a combination of anti-inflammatory and immune-modulating drugs directly… moreThis technology uses lung-targeting lipid nanoparticles to deliver a combination of anti-inflammatory and immune-modulating drugs directly to the lungs, offering a more effective and targeted treatment for acute lung injury and acute respiratory distress syndrome. Background: Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are severe, life-threatening conditions characterized by widespread inflammation and increased permeability in the lungs, often resulting from infection, trauma, or other critical illnesses. These syndromes lead to impaired gas exchange, hypoxemia, and respiratory failure, frequently requiring intensive care and mechanical ventilation. Despite advances in supportive care, mortality rates for ALI/ARDS remain high, underscoring the urgent need for more effective therapeutic interventions. The complexity of these conditions, which involve dysregulated immune responses and extensive lung tissue damage, has driven ongoing research into targeted therapies that can modulate inflammation and promote tissue repair directly within the lungs. Current treatment strategies for ALI/ARDS are largely supportive, focusing on mechanical ventilation and fluid management, with pharmacological interventions offering only modest benefits. Conventional drugs such as corticosteroids, neuromuscular blockers, and inhaled nitric oxide have shown limited efficacy in improving patient outcomes, and many promising agents—including antioxidants, statins, surfactant therapy, and cytokine inhibitors—have failed to demonstrate consistent clinical benefit. One major limitation of existing approaches is the lack of targeted delivery to lung tissue, resulting in suboptimal drug concentrations at the site of injury and increased risk of systemic side effects. Furthermore, most therapies address only a single aspect of the disease process, rather than the multifaceted immune and inflammatory pathways involved in ALI/ARDS, leaving a significant gap in effective, comprehensive treatment options. Technology Overview: This technology utilizes specialized lung-targeting lipid nanoparticles (LNPs) designed for the intravenous delivery of multiple therapeutic agents to treat acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). The LNPs are engineered to transport a combination of an anti-inflammatory drug and immune modulators directly to lung tissue. By leveraging the unique properties of lipid nanoparticles, this approach enables precise targeting of the lung, ensuring that the therapeutic agents are delivered efficiently to the site of injury. Preclinical studies in mouse models have demonstrated that this multi-agent delivery system can enhance localized therapeutic effects, potentially offering a more effective treatment for ALI/ARDS compared to conventional therapies. What differentiates this technology is its multi-modal, lung-specific delivery strategy, which addresses several key limitations of current ALI/ARDS treatments. Traditional therapies often suffer from limited efficacy and significant systemic side effects due to non-specific drug distribution. In contrast, the LNP system’s ability to co-deliver synergistic agents directly to the lungs allows for simultaneous suppression of inflammation, modulation of immune responses, and targeted inhibition of specific inflammatory pathways. This integrated approach not only maximizes therapeutic efficacy but also minimizes off-target effects, representing a significant advancement over existing non-targeted therapies. The innovation lies in the combination of targeted delivery, multi-agent synergy, and the potential for improved patient outcomes, positioning this technology as a transformative solution for severe lung injuries. https://suny.technologypublisher.com/files/sites/adobestock_221990236.jpeg Advantages: • Targeted delivery of therapeutic agents specifically to lung tissue enhances treatment efficacy for ALI/ARDS. • Combination of anti-inflammatory, immunomodulatory, and pathway-specific inhibitors provides a multi-modal therapeutic approach. • Intravenous administration of lipid nanoparticles enables efficient and localized drug delivery. • Potential to reduce systemic side effects compared to conventional treatments. • Demonstrated promising efficacy in preclinical mouse models of lung injury. • Addresses significant unmet medical needs in treating acute lung injury and respiratory distress syndrome. • Innovative use of proprietary lung-targeting lipid nanoparticles as a delivery platform for multiple complementary agents in one system. Applications: • ALI/ARDS hospital treatment enhancement • Targeted drug delivery for lungs • Acute respiratory failure emergency care Intellectual Property Summary: Patent application: 63/813,654, filed on 05/29/2025 Stage of Development: TRL 3 Licensing Status: This technology is available for licensing. less |
Primary:
Research Foundation of SUNY
Date posted: Jan 16, 2026 |
|
|
Metamaterial Adhesives for Packaging, Hanging, and Handling
OUR SOLUTION
Figure: 3D Design of the Adhesive. Advantages:
Potential Application:
less |
Primary:
Virginia Tech Intellectual Properties Inc
Date posted: Jan 16, 2026 |
|
|
Composition and Methods for Preparing Orally Bioavailable Guanidine Prodrugs
OUR SOLUTION
Advantages:
Potential Application:
less |
Primary:
Virginia Tech Intellectual Properties Inc
Date posted: Jan 16, 2026 |
|
|
3D-printed instrument for equine chondroid removal
OUR SOLUTION
Figure: Custom 3D-printed instrument and cadaveric head set-up. Advantages:
Potential Application:
less |
Primary:
Virginia Tech Intellectual Properties Inc
Date posted: Jan 16, 2026 |
|
|
Electrolytes Comprising a Rigid Polymer, Salt, and Salt-Coordinating Molecules
OUR SOLUTION
Figure: Overview of the technology. Advantages:
Potential Application:
less |
Primary:
Virginia Tech Intellectual Properties Inc
Date posted: Jan 16, 2026 |
|
|
Method and Apparatus for Efficient Credential Revocation Mechanism in Metaverse
OUR SOLUTION
Advantages:
Potential Application:
less |
Primary:
Virginia Tech Intellectual Properties Inc
Date posted: Jan 16, 2026 |